Cimzia® (certolizumab pegol)(NO LONGER ENROLLING)

Thank you for your interest, but unfortunately, we are no longer enrolling participants in this study. However, you may be eligible to participate in one of our other ongoing studies. Fill out your information using our Join a Study form, and a member of our team will contact you.

We’re Collecting Info on CIMZIA® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of CIMZIA® (certolizumab pegol) when taken during pregnancy to treat ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, and/or rheumatoid arthritis. Our research is by observation only—we will not ask you to take or change any medications. If you join our CIMZIA® study, our team will simply collect some information about your pregnancy and your baby’s development for a period of time after birth. If you have taken CIMZIA® during your current pregnancy, you may qualify for this important study.

Find out more below!

Join a Study

REfer A PAtient

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We’re open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work

Parent-To-Be Enrolls in Study

We Gather Info about the Pregnancy

Discoveries & Insights Gained

What’s Involved?

Our study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your and your baby’s medical records from your healthcare providers.
• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor

MotherToBaby Pregnancy Women Intro Block

What is MotherToBaby Pregnancy Studies?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego’s Center for Better Beginnings. She is a world‐renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

“Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes.”

– Christina Chambers, PhD, MPH

Will you take the next step and help us learn more about the use of CIMZIA® during pregnancy?

Cimzia® (certolizumab pegol)(NO LONGER ENROLLING)

We’re Collecting Info on Kesimpta® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of Kesimpta® (ofatumumab) when taken within 5 1/2 months before or during pregnancy. Our studies are strictly observational, which means we will never ask you to take any new medicines, experimental drugs or to change any part of your healthcare routine. If you enroll, you’ll simply be followed by our team through the remainder of your pregnancy, and your baby will be followed for a period of time after birth. Eligible moms-to-be who enroll in the study may receive up to $250 to compensate them for the time they spend completing study activities.

Our goal is to provide parents and their health providers with the evidence-based information that they need to make more informed healthcare decisions during pregnancy. To do that, we need your help. If you have multiple sclerosis and have taken Kesimpta® (ofatumumab) at any point in your current pregnancy, or shortly prior to pregnancy, you may qualify for this important study.

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We’re open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work

Parent-To-Be Enrolls in Study

We Gather Info about the Pregnancy

Discoveries & Insights Gained

What’s Involved?

Our Kesimpta® (ofatumumab) study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your medical records from your healthcare provider for your pregnancy and for your child through 1 year of age.
• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor
• An online neurodevelopmental assessment that can also provide insight into the child’s development at approximately 12 months of age

Thank You for Participating: Compensation for Moms Who Take Part

We know your time is valuable. To thank you for the time you’ll be spending on study activities, you will receive $50 for each activity listed below.

Celebrated Study Milestones – Up to $250 in total compensation!

$50 for completing our enrollment interview and returning the signed form to release your pregnancy-related medical records to the study
$50 for completing the phone interview that will take place around the 20-week mark of your pregnancy
$50 for completing the phone interview that will take place around the 32-week mark of your pregnancy
$50 for completing the phone interview that will take place after the end of your pregnancy and returning the signed form to release to the study the medical records related to the outcome of your pregnancy
$50 for completing the child development questionnaire (the Ages and Stages Questionnaire) and returning the signed form to release your child’s pediatric medical records to the study

✔ You will be compensated at the time each study activity is completed

✔ There’s no penalty if you choose not to complete every study activity

✔ Participation in our study never changes your med

All the information we request will be kept confidential. Your privacy is important to us. We comply with strict regulations
and laws set forth by state and federal agencies as well as the Institutional Review Board (IRB) at the University of
California, San Diego, who oversees and monitors our research. Since we ask for your permission to obtain medical
records, we will also give you detailed information on how this data will be used and how we will protect your privacy.

What is a MotherToBaby Pregnancy Study?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego’s Center for Better Beginnings. She is a world‐renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

“Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes.”

– Christina Chambers, PhD, MPH

If you are interested in joining the study, please submit your interest below. Our research team will contact you to see if you qualify. Your information is confidential.

If you are a health professional, please fill out the Refer a Patient form and we will contact your patient to see if they qualify. Your information is confidential.

Cimzia® (certolizumab pegol)(NO LONGER ENROLLING)

We’re Collecting Info on BOOSTRIX When Taken in Pregnancy

MotherToBaby is currently enrolling pregnant people who received (or plan to receive) the BOOSTRIX Tdap vaccine in an observational study. This vaccine is recommended during the 3^rd trimester of pregnancy to prevent pertussis (whooping cough) in infants under the age of 2 months. If you have already received the Tdap vaccine during the third trimester of your pregnancy or you plan to do so, we invite you to join our observational study. Participation involves providing information about your pregnancy and your baby’s development for a certain period of time after birth.

Please note that we will not ask you to receive the Tdap vaccine as part of the study; we are solely interested in gathering data from those who have already chosen to receive BOOSTRIX during the third trimester of pregnancy. If you meet this criteria, you may be eligible to participate.

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We’re open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work

Parent-To-Be Enrolls in Study

We Gather Info about the Pregnancy

Discoveries & Insights Gained

What’s Involved?

Our BOOSTRIX study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your medical records from your healthcare provider for your pregnancy and for your child through 1 year of age.

All the information you provide will be kept confidential. Your privacy is important to us. We comply with strict regulations and laws set forth by state and federal agencies as well as the Institutional Review Board (IRB) at the University of California, San Diego, who oversees and monitors our research. Since we ask for your permission to obtain medical records, we will also give you detailed information on how this data will be used and how we will protect your privacy.

What is a MotherToBaby Pregnancy Study?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego’s Center for Better Beginnings. She is a world‐renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

“Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes.”

– Christina Chambers, PhD, MPH

If you are interested in joining the study, please submit your interest below. Our research team will contact you to see if you qualify. Your information is confidential.

If you are a health professional, please fill out the Refer a Patient form and we will contact your patient to see if they qualify. Your information is confidential.

The BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine) Pregnancy Study conducted by MotherToBaby and is sponsored by GSK.

Cimzia® (certolizumab pegol)(NO LONGER ENROLLING)

Providing Better Information on Medication Safety in Pregnancy and Breastfeeding

Pregnancy studies, also known as pregnancy exposure registries, gather valuable information about how medications, vaccines, and health conditions might affect a pregnancy. These studies are observational, which means participants are not asked to take medications or make changes to their medical treatments or healthcare choices. Some participants may be taking medications or received vaccines, while others have not. Similarly, some participants may have health conditions, while others may not. The studies follow participants through their pregnancy—and sometimes follow the infants after birth, collecting information along the way. The information helps researchers learn if the medications, vaccines, or health conditions might affect pregnancy outcomes, such as increasing or lowering the chances of birth defects, preterm delivery, or other complications.

Breastfeeding studies help provide more information about how medications, vaccines, or other exposures could affect breast milk or the growth and development of breastfed children. These studies enroll people who are breastfeeding or pumping while taking certain medications or vaccines, as well as those who are not taking medications or vaccines. Participants are not asked to make any changes to their medical treatments or healthcare choices. Participants provide milk samples and information about their child’s health to researchers as the child grows. Researchers can use this information to learn whether the medications or vaccines can get into the milk, change the milk, or have an effect on a child’s growth and development.

In order to help provide information to even more individuals and families about medications and vaccines in pregnancy and while breastfeeding, MotherToBaby encourages participation in the following pregnancy and breastfeeding studies. Please contact MotherToBaby at the link below for more information about opportunities to participate:

Get STUDY Info

Join a Study

People who are pregnant and/or breastfeeding deserve better information about medication safety – and you can help by participating in a study.

Make a Difference

Cimzia® (certolizumab pegol)(NO LONGER ENROLLING)

Helping You Educate Your Pregnant and Breastfeeding Patients

MotherToBaby welcomes the opportunity to partner with you on educating your patients about exposures during pregnancy and breastfeeding. We’d also love to partner with you on improving the quality of medication safety information by enrolling your patients in our observational research studies. Please consider referring your patients to our exposure information service and/or our pregnancy studies research program.

Refer NOw

We Provide Exposure Information to Patients

Our experts are trained in assessing and evaluating risks to pregnancy and breastfeeding outcomes from medications and other exposures, including but not limited to maternal health conditions, infections and vaccines, substances of abuse, and workplace exposures. We conduct a thorough review of the current scientific literature to provide evidence-based information to your patients in a way they will understand. You can refer your patient for exposure information using our Patient Referral Form. If you would prefer to interact directly with one of our teratogen information specialists by phone, text, email, or chat, visit our Ask An Expert page.

Pregnancy Studies

As a health provider who treats patients of reproductive age, you may be as frustrated as we are by the lack of data regarding the effects of many medications on pregnancy outcomes. Our rigorously designed observational studies aim to provide this much-needed information, ultimately helping you and your patients better navigate treatment decisions and other complex issues during pregnancy. Your patient will not be asked to take or change any medications. People self-enroll, so after you refer a patient nothing further is required from you. You can refer your patient to our studies using our online study referral form. If you would prefer to speak directly to a member of our research team, call 877.311.8972.

Patient Education

Our easy-to-read Fact Sheets on exposures in pregnancy and breastfeeding are available in English and Spanish.

Exlore Now